BioMarin’s Gene Therapy Roctavian More Cost-Effective in Hemophilia A than Genentech and Chugai’s Hemlibra

September 26th, 2022|Categories: Featured, Industry News|Tags: , , , , |

ICER has released a draft report that indicates Roctavian, BioMarin’s new gene therapy for hemophilia A, will beat the current antibody-based therapeutic Hemlibri. Unlike Hemlibri, which is a prophylactic, Roctavian restores the gene lacking in hemophilia A, factor VIII. The organization predicts that the one-time price of $2.5 million for Roctavian will be substantially lower than that of 12 years worth of Hemlibra at $640,000 annually.

Go to Top